SCHEMBL6469684

SCHEMBL6469684

COCCOc1ccc2nc(Nc3nc(OC(=O)C(F)(F)F)c4cc(N)cc(C)c4n3)nc(C)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
GAA P10253 1/20 0.38
ALDH1A1 P00352 7/20 0.36
USP2 O75604 2/20 0.36
LMNA P02545 2/20 0.36
RAB9A P51151 1/20 0.36
MAPT P10636 7/20 0.35
AURKA O14965 1/20 0.35
TDP1 Q9NUW8 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
HSD17B10 Q99714 2/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
TDP2 O95551 1/20 0.34
STAT3 P40763 1/20 0.34
TSHR P16473 1/20 0.34
ERBB2 P04626 1/20 0.34
PSMD14 O00487 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6470555 0.90 KDM4E (0.44) KDM4EMEN1KMT2AALDH1A1USP2
SCHEMBL6466218 0.89 SRC (0.38) KDM4EMEN1KMT2AGAAALDH1A1
SCHEMBL6470135 0.88 KMT2A (0.34) KDM4EMEN1KMT2AGAAALDH1A1
Trifluoroacetic Acid SCHEMBL6469682 0.87 KDM4E (0.39) KDM4EMEN1KMT2AGAAALDH1A1
SCHEMBL6470468 0.84 ADORA2A (0.39) KDM4EMEN1KMT2AGAAALDH1A1
SCHEMBL6466266 0.84 RAF1 (0.39) KDM4EMEN1KMT2AGAAALDH1A1
SCHEMBL6467461 0.83 KDM4E (0.44) KDM4EMEN1KMT2AALDH1A1USP2
SCHEMBL6467860 0.82 AURKA (0.39) KDM4EMEN1KMT2AGAAALDH1A1
SCHEMBL6469602 0.81 MAPT (0.38) MEN1KMT2AMAPTMITF
SCHEMBL6469267 0.80 TDP2 (0.46) KDM4EMEN1KMT2AALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB KDM4E 3225/4885MEN1 4218/4885KMT2A 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.